Table I.
Frequency of autoantibodies to thirteen TAAs in ovarian cancer.
| No. (%) of autoantibodies to |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sera | No. tested |
Survivin | p53 | p16 | Cyclin B1 | Cyclin D1 | Cyclin A | Cyclin E | koc | IMP 1 | p62 | CDK2 | p90 | c-myc | Cumulative to 13 antigens |
| OCa | 32 | 7b (21.9) | 8b (25.0) | 8b (25.0) | 8b (25.0) | 8b (25.0) | 6b (18.8) | 7b (21.9) | 6b (18.8) | 3 (9.4) | 3 (9.4) | 3a (9.4) | 3a (9.4) | 1 (3.1) | 20b (62.5) |
| NHS | 82 | 2 (2.4) | 2 (2.4) | 1 (1.2) | 2 (2.4) | 1 (1.2) | 0 (0.0) | 0 (0.0) | 1 (1.2) | 2 (2.4) | 1 (1.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 12 (14.6) |
OCa, ovarian cancer; NHS, normal human sera. Cut-off value: mean ± 3 SD of NSH; p-values between cancer and NHS:
a
p<0.05,
b
p<0.01.